Gilenya and Csf protein increased - a phase IV clinical study of FDA data

Summary:

Csf protein increased is reported as a side effect among people who take Gilenya (fingolimod), especially for people who are female, 20-29 old, have been taking the drug for 1 - 6 months also take Amisulpride, and have Depression.

The phase IV clinical study analyzes which people have Csf protein increased when taking Gilenya. It is created by eHealthMe based on reports of 111,612 people who have side effects when taking Gilenya from the FDA, and is updated regularly.

What is Gilenya?

Gilenya has active ingredients of fingolimod. It is often used in multiple sclerosis. eHealthMe is studying from 111,893 Gilenya users. Check the latest studies of Gilenya.

What is Csf protein increased?

Csf protein increased is found to be associated with 169 drugs and 358 conditions by eHealthMe. Check the latest studies of Csf protein increased.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 26, 2026

111,612 people reported to have side effects when taking Gilenya.
Among them, 70 people (0.06%) have Csf protein increased.

Could Gilenya cause Csf protein increased?

Among these 70 people:

How long have people been on Gilenya when they have Csf protein increased? *

What is the gender of people who have Csf protein increased when taking Gilenya? *

female: 91.18 %
male: 8.82 %

What is the age of people who have Csf protein increased when taking Gilenya? *

What are other drugs people take besides Gilenya? *

What are other side effects people have besides Csf protein increased? *

Central Nervous System Lesion (an abnormality in tissue of brain or spinal cord): 44 people, 62.86%
Hemiparesis (weakness on one side of the body): 39 people, 55.71%
Loss Of Consciousness: 36 people, 51.43%
Demyelination (loss of the myelin covering of some nerve fibres resulting in their impaired function): 34 people, 48.57%
Headache (pain in head): 33 people, 47.14%
Cognitive Disorder (mental health disorders affects learning, memory, perception, and problem solving): 33 people, 47.14%
Stroke (sudden death of a portion of the brain cells due to a lack of oxygen): 31 people, 44.29%
Confusional State: 30 people, 42.86%
Dizziness: 27 people, 38.57%
Nausea (feeling of having an urge to vomit): 26 people, 37.14%

What are the existing conditions these people have? *

Depression: 22 people, 31.43%
Paresis (a condition of muscular weakness): 9 people, 12.86%
Headache (pain in head): 8 people, 11.43%
Type 2 Diabetes: 4 people, 5.71%
Diabetes: 2 people, 2.86%
Pain: 2 people, 2.86%
High Blood Pressure: 1 person, 1.43%
Epilepsy (common and diverse set of chronic neurological disorders characterized by seizures): 1 person, 1.43%
Herpes Zoster: 1 person, 1.43%
Optic Neuritis (optic nerve inflammation): 1 person, 1.43%

* Approximation only. Some reports may have incomplete information.

Do you take Gilenya and have Csf protein increased?

- Check whether Csf protein increased is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Gilenya:

Gilenya (111,893 reports)

Browse all side effects of Gilenya:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Csf protein increased:

Csf protein increased (169 drugs)

Browse all the conditions that are associated with Csf protein increased:

Csf protein increased (358 conditions)

Related publications that referenced our studies

Christopher KL, Elner VM, Demirci H, "Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis", Ophthalmic Plastic & Reconstructive Surgery, 2017 May .
Alroughani R, "Fingolimod-associated amenorrhea: a report of three cases", Multiple Sclerosis Journal, 2014 Jan .
Christopher, K. L., Elner, V. M., & Demirci, H. , "Conjunctival lymphoma in a patient on fingolimod for relapsing-remitting multiple sclerosis", Ophthalmic plastic and reconstructive surgery , 2014 Jan .
Christopher KL, Elner VM, Demirci H, "Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis", Ophthalmic Plastic & Reconstructive Surgery, 2017 May .
Alroughani R, "Fingolimod-associated amenorrhea: a report of three cases", Multiple Sclerosis Journal, 2014 Jan .
Christopher, K. L., Elner, V. M., & Demirci, H. , "Conjunctival lymphoma in a patient on fingolimod for relapsing-remitting multiple sclerosis", Ophthalmic plastic and reconstructive surgery , 2014 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on fingolimod (the active ingredients of Gilenya) and Gilenya (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.